Rated Speculative Buy, $0.51 Price Target DALLAS, March 11 /PRNewswire-FirstCall/ -- Crdentia Corp. (OTC:CRDT) (BULLETIN BOARD: CRDT) , a leading healthcare staffing company, today announced that Wasserman Morris & Company, an independent investment research firm, initiated coverage on the Company with a 'Speculative Buy' rating and a price target of $0.51 per share. The report is available at http://www.crdentia.com/corporate/about/investor/ and through http://www.wassermanmorris.com/. About Crdentia Corp. Crdentia Corp., one of the nation's leading providers of healthcare staffing solutions, is focused on recruiting talented national and international healthcare professionals to meet the ever-increasing employment needs of over 2,300 clients. Crdentia is one of the few companies that can provide quality temporary staff for all healthcare industry positions including local nurses, travel nurses, allied health, locum tenens and home care professionals. For more information, visit http://www.crdentia.com/. Forward Looking Statements Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q, and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to, a limited operating history with no earnings; reliance on the Company's management team, members of which have other business interests; the ability to successfully implement the Company's business plan; the ability to continue as a going concern; the ability to fund the Company's business and acquisition strategy; the growth of the temporary healthcare professional staffing business; difficulty in managing operations of acquired businesses; uncertainty in government regulation of the healthcare industry; and the limited public market for the Company's common stock. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. Crdentia undertakes no obligation to revise or update publicly any forward-looking statements for any reason. Contact Crdentia Corp. John Kaiser, CEO Phone: 972.850.0780 Fax: 972.392.2722 Jim TerBeest, CFO Phone: 972.850.0780 Fax: 972.392.2722 DATASOURCE: Crdentia Corp. CONTACT: John Kaiser, CEO, +1-972-850-0780, fax, +1-972-392-2722, , or Jim TerBeest, CFO, +1-972-850-0780, fax, +1-972-392-2722, , both of Crdentia Corp.

Copyright